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Abstract
Folate-mediated one carbon (1C) metabolism supports a series of processes that are essential for the cell. Through a number
of interlinked reactions happening in the cytosol and mitochondria of the cell, folate metabolism contributes to de novo
purine and thymidylate synthesis, to the methionine cycle and redox defence. Targeting the folate metabolism gave rise to
modern chemotherapy, through the introduction of antifolates to treat paediatric leukaemia. Since then, antifolates, such as
methotrexate and pralatrexate have been used to treat a series of blood cancers in clinic. However, traditional antifolates have
many deleterious side effects in normal proliferating tissue, highlighting the urgent need for novel strategies to more
selectively target 1C metabolism. Notably, mitochondrial 1C enzymes have been shown to be significantly upregulated in
various cancers, making them attractive targets for the development of new chemotherapeutic agents. In this article, we
present a detailed overview of folate-mediated 1C metabolism, its importance on cellular level and discuss how targeting
folate metabolism has been exploited in blood cancers. Additionally, we explore possible therapeutic strategies that could
overcome the limitations of traditional antifolates.
Introduction
Cancer cells undergo metabolic changes to harness nutrients
and support their rapid growth and proliferation. Such
metabolic reprogramming has been extensively studied. The
first evidence for changes in cancer metabolism were
observed by Otto Warburg during the early 20th century.
Warburg described an increase in aerobic glycolysis,
‘Warburg effect’, where cancer cells took up and fermented
glucose to lactate in the presence of oxygen. Metabolic
alterations have been exploited by researchers ever since, in
order to understand tumour growth and metastatic dis-
semination [1, 2].
Folate metabolism, considered the core of a broader set
of transformations known as one-carbon (1C) metabolism,
allows the transfer of 1C units for biosynthetic purposes
such as de novo synthesis of adenosine, guanosine and
thymidylate and for methylation reactions that support the
methionine cycle. As animals cannot synthesise folate,
insufficient dietary intake can cause neural tube defects in
developing foetuses and anaemia [3–5].
With regards to the association of the folate metabolism
to blood cancers, the idea that antagonists of folates could
reduce the proliferation of malignant cells in paediatric
leukaemia gave rise to modern cancer therapy and a class of
drugs known as antifolates [6]. Since then, methotrexate
(MTX), likely the most well-known antifolate, has been
used to treat a variety of neoplastic and inflammatory dis-
eases. Analysis of publicly available data on the sensitivity
of almost 700 cancer cell lines to MTX demonstrates that
haematological cancer cell lines show high sensitivity to
this antifolate, with acute lymphoblastic leukaemia (ALL)
and acute myeloid leukaemia (AML) cell lines displaying
the highest sensitivity (Fig. 1) [7]. These data suggest that
targeting 1C metabolism might be an appealing option for
the treatment of various blood cancers. Interestingly, MTX
is routinely used only in the treatment of ALL and central
nervous system (CNS) lymphoma, even though all blood
cancer cell lines demonstrate high sensitivity. As further
discussed below, limited application of MTX is linked to
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resistance mechanisms that cancer cells acquire to minimise
the effectiveness of antifolates [8, 9]. For instance, AML
blasts have a decreased ability to retain substantial MTX
levels intracellularly [10]. Furthermore, antifolates, which
broadly inhibit folate-mediate reactions, can manifest a
series of side effects in normal proliferating tissue, such as
damage to the gastrointestinal epithelium and impaired
haematopoiesis [11, 12]. Resistance to antifolates and
adverse side effects highlight the growing need for novel
strategies to target 1C metabolism.
Folate cycle and compartmentalisation
Folate metabolism occurs in two parallel and com-
plementary pathways, localised in the cytosol and mito-
chondria (Fig. 2). New 1C units are donated from amino
acids such as serine (the primary source of 1C units),
glycine (through the glycine cleavage system) and the
choline degradation products dimethylglycine and
methylglycine (sarcosine), while folate molecules func-
tion as 1C unit carriers. In brief, the first step of the
reaction is catalysed by serine hydroxymethyl transferase,
SHMT1 (cytoplasmic) and SHMT2 (mitochondrial),
where serine gets converted to glycine and its 1C unit is
donated to tetrahydrofolate (THF) to give rise to 5,10-
methylene-THF. In the cytosol, 5,10-methylene-THF
contributes to thymidylate synthesis and the methionine
cycle. Interestingly, SHMT2 was found to contribute to
mitochondrial translation by providing methyl donors for
the taurinomethyluridine synthesis [13]. 5,10-methylene-
THF is then converted to the most oxidised form of folate
carbon, 10-formyl-THF. In the cytosol, this conversion is
carried out by the trifunctional enzyme methylene-THF
dehydrogenase 1 (MTHFD1) with a 5,10-methylene-THF
dehydrogenase, 5,10-methenyl-THF cyclohydrolase and
10-formyl-THF synthase activity. Whereas in the mito-
chondria, it is the bifunctional methylene-THF dehy-
drogenase 2 (MTHFD2) or 2 like (MTHFD2L) with
dehydrogenase and cyclohydrolase activity that catalyses
the conversion. Nilsson et al. [14] demonstrated that
normal and cancer cells express both enzymes, even
though MTHFD2 exhibits a higher baseline expression.
Surprisingly, MTHFD2L exhibited a greater increase in
cancer tissue versus normal tissue in AML compared to
MTHFD2,. In general, MTHFD2L was unable to com-
pensate for the loss of MTHFD2 and it did not show any
association with proliferation or response to growth fac-
tors. Cytosolic 10-formyl-THF is essential for de novo
purine synthesis. More specifically, for every newly syn-
thesised DNA or RNA base, one molecule of 10-formyl-
THF is required [2, 15]. Mitochondrial 10-formyl-THF is
used to initiate mitochondrial translation by producing
formyl-methionine tRNA. Additionally, as 10-formyl-
THF cannot cross the mitochondrial membrane, it first
gets hydrolysed to formate by the MTHFD1-like enzyme.
Lastly, 10-formyl-THF can be fully oxidised to CO2, a
reaction catalysed by 10-formyltetrahydrofolate dehy-
drogenase 1 (ALDH1L1) or 2 (ALDH1L2) in the cytosol
or mitochondria respectively, leading to its terminal
elimination.
Fig. 1 Haematological cancer cell lines show high sensitivity to
methotrexate. IC50 values for methotrexate across several cell lines
as obtained by the publicly available database Genomics of Drug
Sensitivity in Cancer (https://www.cancerrxgene.org/). Number in
parenthesis represents number of cell lines analysed per each cancer
type. ALL, acute lymphoblastic leukaemia; AML, acute myeloid
leukaemia; CLL, chronic lymphoblastic leukaemia; CML, chronic
myeloid leukaemia; DLBC, diffuse large B-cell lymphoma; MM,
multiple myeloma; ACC, adrenocortical carcinoma; BLCA, bladder
urothelial carcinoma; LGG, brain lower grade glioma; BRCA, breast
invasive carcinoma; CESC, cervical squamous cell carcinoma and
endocervical adenocarcinoma; COREAD, colon and rectum adeno-
carcinoma; ESCA, oesophageal carcinoma; GBM, glioblastoma mul-
tiforme; HNSC, head and neck squamous cell carcinoma; KIRC,
kidney real clear cell carcinoma; HCC, hepatocellular carcinoma;
LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma;
MB, medulloblastoma; MESO, mesothelioma; NB, neuroblastoma;
OV, ovarian serous cystadenocarcinoma; PDAC, pancreatic adeno-
carcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous
melanoma; SCLC, small cell lung carcinoma; STAD, stomach ade-
nocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus
endometrial carcinoma.
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The presence of these two parallel pathways allows for a
complete oxidative/reductive cycle, where serine gets cat-
abolized in the mitochondria and then synthesised in the
cytosol. Interestingly, studies have revealed that this sub-
cellular compartmentalisation is conserved from yeast to
mammalian cells [16]. Ducker et al. [17] using a serine
tracer that was developed to distinguish the mitochondrial-
derived serine contribution versus the cytosolic [18, 19],
demonstrated that most cultured cell lines generate 1C units
exclusively in the mitochondria and that mitochondrial-
released formate directly contributes to nucleotide and
serine synthesis. Interestingly, the same and consecutive
studies have shown that genetic inhibition of mitochondrial
1C enzymes induces a rewiring of the flux, where the
cytosolic pathway switches from serine synthesis to serine
catabolism [17, 20]. Cells end up becoming glycine auxo-
trophs, depending on extracellular glycine, as the cytosolic
pathway cannot compensate for the loss of mitochondrial
glycine production [21]. Labuschagne et al. [22] showed
that in the absence of serine, exogenous glycine is unable to
support nucleotide synthesis as cells start using glycine for
serine synthesis.
Fig. 2 An overview of folate-mediated 1C metabolism and its
compartmentalisation. From yeast to mammalian cells 1C units tend
to flow clockwise allowing for a complete oxidative/reductive cycle
where serine gets oxidised in the mitochondrial compartment and
formate gets reduced in the cytosol. Through this intercompartmental
cycle folate metabolism supports anabolic reactions such as purine and
thymidylate synthesis as well as the methionine cycle. DHF, dihy-
drofolate; THF, tetrahydrofolate; DHFR, dihydrofolate reductase;
MFT, mitochondrial folate transporter; SHTMT1/2, serine
hydroxymethyl transferase, cytosolic (1)/ mitochondrial (2);
MTHFD1, methylenetetrahydrofolate dehydrogenase 1; MTHFD2(L),
methylenetetrahydrofolate dehydrogenase 2 (2-like); MTHFD1L,
monofunctional tetrahydrofolate synthase; TYMS, thymidylate syn-
thetase; MTHFR, methylenetetrahydrofolate reductase; GART, phos-
phoribosylglycinamide formyltransferase; ATIC, 5-aminoimidazole-4-
carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase;
ALDH1L1/2, 10-formyltetrahydrofolate dehydrogenase cytosolic (1)/
mitochondrial (2).
Folate metabolism: a re-emerging therapeutic target in haematological cancers
A number of studies have tried to shed light on the
compartmentalisation and directionality of folate metabo-
lism. Conversion of 5,10-methylene-THF to 5,10-methenyl-
THF by MTHFD2 is accompanied by mitochondrial NAD
(P)H production. Whereas the reverse reaction catalysed by
MTHFD1 in the cytosol proceeds in a NADPH-consuming
direction [17, 23, 24]. The difference in electrochemical
potential between NADH and NADPH explains the direc-
tionality of folate metabolism, where mitochondrial formate
gets shuttled to the cytosol. With regards to why there
should be a mitochondrial compartment in the first place,
Zheng et al. [25] conclude that the existence of the mito-
chondrial compartment provides the necessary flexibility to
balance cellular demands for glycine and 1C units.
Whereas, a single cytosolic compartment would probably
overwhelm the cell, as it would require multiple complex
regulatory mechanisms (similar to E. coli where there is a
single compartment). Additionally, Ducker and Rabinowitz
[2] suggest that most of serine catabolism is localised in the
mitochondria to separate 1C metabolism from glycolysis
that happens in the cytosol. They argue that NADH pro-
duction from the conversion of 5,10-methylene-THF to
5,10-methenyl-THF could deplete the cytosolic NAD+ pool
needed for glycolysis. Overall, it seems that nature and
evolution have enabled this compartmentalisation to max-
imise efficiency.
Formate overflow and its implications
Several studies have reported that formate production
through serine catabolism exceeds the 1C demands for
nucleotide synthesis. This excess of formate, also known as
formate overflow, depends on the expression of mitochon-
drial folate enzymes and the oxidative phosphorylation
status of the cells [17, 20, 26, 27]. Meiser et al. [27]
demonstrated that tumours with an active and robust oxi-
dative metabolism are formate overflow positive, describing
this formate overflow as a hallmark of oxidative cancers.
Additionally, the authors revealed that cancer tissues exhibit
significantly higher serine catabolism to formate, compared
to normal adjacent tissue and other non-tumour-bearing
organs. Plasma formate levels were also found to be sig-
nificantly higher in tumour bearing mice compared to wild-
type mice.
There are various hypotheses for the selective advantage
of formate overflow, but it is still difficult to make solid
conclusions. When Meiser et al. [27] demonstrated that
formate overflow is a hallmark of oxidative tumours they
also showed that the excess formate released from cancer
cells promoted invasion in vitro. Here it is tempting to
hypothesise that increased mitochondrial 1C metabolism
and consequently formate overflow, might be advantageous
for cancer development as it promotes invasion.
Furthermore, Oizel et al. [28] conclude that formate over-
flow induces a metabolic switch to a cellular state with high
purine and pyrimidine nucleotide levels and an increased
rate of glycolysis. The increase in purine synthesis links
formate overflow with cell signalling. In the process of
increasing purine synthesis, there is a dramatic reduction of
intracellular 1-(5′-Phosphoribosyl)-5-aminoimidazole-4-
carboxamide ribotide (AICAR), the phosphorylated variant
of the AMP activated kinase (AMPK) activating drug aca-
desine. The decrease in AICAR then results in a reduction
of AMPK activity [28]. Concomitantly, the increase in
purine levels promotes an increase in the mammalian target
of rapamycin (mTOR) kinase activity, the master regulator
of cell growth [29]. Ultimately, what they hypothesise is
that serine catabolism to formate is required to trigger this
metabolic switch, which potentially serves as a selective
advantage for the existence of the mitochondrial branch of
folate metabolism.
NADH/NADPH production and its implications
Undeniably, the major role of folate metabolism is its
contribution to nucleotide synthesis. However, more and
more evidence suggest that it is not just nucleotide con-
tribution that might have important implications on a cel-
lular level. Similar to the formate overflow, and its role in
energy metabolism (as a metabolic switch) and invasion,
there is increasing evidence that other by-products of the
folate pathway have important roles in the cell.
NADH production by the mitochondrial MTHFD2 links
1C metabolism to oxidative phosphorylation. NADH is
subsequently oxidised while its electrons are transferred to
the electron transport chain (ETC) complexes. This, ulti-
mately, contributes to energy production in the form of
ATP. Remarkably, Ducker et al. [17] demonstrated that
serine catabolism contributes to up to 7% of the NADH
pool. In addition, formate production correlates with the
respiration status of the cell, where ETC impairment upon
treatment with ETC inhibitors (i.e. rotenone, metformin) or
mitochondrial DNA depletion, causes a reduction of for-
mate release from the cells [20, 21, 26]. Interestingly, Bao
et al. [26] showed that respiration chain dysfunction induces
an adaptive response to increase serine synthesis (1C donor)
to feed the mitochondrial 1C pathway. Furthermore, Yang
et al. [30] described that upon respiration impairment, serine
catabolism becomes a major source of NADH, whereas the
other NADH sources like glutamine, fatty acid oxidation
and lactate are blocked. This persistence of serine catabo-
lism contributes to an accumulation of NADH that can be
toxic. Inhibition of serine catabolism in the context of
impaired respiration can normalise NADH levels and
facilitate cell growth. However, previous studies have
reported a synergistic effect in growth inhibition when 1C
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metabolism (via serine deprivation) and ETC are impaired
[31, 32]. What one can say with certainty is that there is a
definitive link between cellular respiration and 1C meta-
bolism and it is worth of further investigation.
The oxidation step of methylene-THF to 10-formyl-THF
is coupled to production of NADPH. In addition, full oxi-
dation of 10-formyl-THF to CO2 also contributes to
NADPH [23, 24]. NADPH is primarily synthetised through
the pentose phosphate pathway (PPP) and provides high-
energy electrons for antioxidant defence and reductive
biosynthesis such as fatty acid and proline synthesis.
Interestingly, to date there are two connections of folate
metabolism to NADPH. The first connection is the pro-
duction of NADPH via 1C metabolism and the second is
that NADPH production through the PPP supports the folate
pathway via regulation of the dihydrofolate reductase
(DHFR) activity [33]. In a cancer context, evidence sug-
gests that upregulation of mitochondrial 1C metabolism
contributes to cancer progression by supporting an anti-
oxidant defence. Ye et al. [34] described that in MYC
amplified cancer cell lines and neuroblastoma patient sam-
ples, SHMT2 gets induced to produce NADPH (by initiating
the degradation of serine to CO2) and to maintain redox
balance under hypoxic conditions. Ducker et al. [17] also
demonstrated that cell lines deficient in MTHFD2 and
ALDH1L2 were sensitised to hydrogen peroxide, a form of
oxidative stress. Piskounova et al. [35] showed that folate
pathway inhibition by MTX, ALDH1L2 knockdown or
MTHFD1 knockdown inhibited tumour metastasis, con-
cluding that ALDH1L2 counteracts oxidative stress and
promotes metastasis. On that note, it was recently shown
that cybrid cells (cells produced by combining cytoplasm of
nucleated cells with non-nucleated cells or cytoplasts) with
a mutation in a gene encoding an integral component of
Complex I subunit of the ETC display a reduction in serine
catabolism and NADPH production that leads to oxidative
stress, inflammation and ultimately, cell death [36]. While
in HCT116 cells, both ALDH1L1 and ALDH1L2 expression
is minimal, suggesting that the folate pathway does not
contribute substantially to NADPH, ALDH1L2 expression
is found to be upregulated in several tumour types [37]. It
would be interesting to gain a better insight into this upre-
gulation that suggests that specific tumours would require
NADPH for an antioxidant response, therefore making them
more vulnerable to oxidative stress.
Targeting 1C metabolism in blood cancers
Since the late 40 s when Sydney Farber administered a
newly synthesised folate analogue (aminopterin) to children
with ALL, antifolates targeting 1C metabolism have been
used to treat a wide range of cancers including haemato-
logical malignancies (Table 1). MTX, the most frequently
used antifolate, has been approved by the Food and Drug
Administration for the prophylaxis of meningeal leukaemia
and it is also used in maintenance therapy with other che-
motherapeutic drugs in patients with ALL [38]. MTX
treatment, followed by whole-brain radiation, is the mostly
commonly used approach for patients diagnosed with a rare
form of non-Hodgkin lymphoma, CNS lymphoma [39].
MTX enters the cell via the reduced folate carrier
(RFC1), encoded by SLC19A1, a protein found pre-
dominantly in the cell membranes of foetal and cancer cells
(Fig. 3). Once in the cytosol, it gets polyglutamated by
folylpolyglutamate synthetase. Polyglutamation is a time-
and concentration-dependent process that ultimately
enhances the action of MTX. Polyglutamates (up to five
additional glutamates) of MTX are retained longer in the
cell, thus the amount accumulated and the length of the
chain of MTX polyglutamates are key determinants of
Table 1 Antifolates and their application in haematological cancers.
Drug Name Enzymatic target Clinical application Reference
Methotrexate DHFR, TYMS and GART/ATIC prophylaxis of meningeal leukaemia




diffuse large B-cell lymphoma
relapsed and refractory ALL
advanced mycosis fungoides (type of
cutaneous T-cell lymphoma)
Izbicka et al. [38]
Ferreri et al. [39]
Batchelor et al. [103]
Schmiegelow et al.
[91]
Kloos et al. [80]
Pralatrexate DHFR, TYMS and GART/ATIC refractory T-cell lymphoma
preclinical models of multiple myeloma
Sirotnak et al. [87]
Kinahan et al. [88]
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antifolate-mediated cytotoxicity. MTX and its poly-
glutamates inhibit DHFR, that catalyses the conversion of
dihydrofolate to THF. Additionally, polyglutamation alters
the cellular effects of MTX, as studies have shown that
MTX polyglu tamates are more potent inhibitors of other
folate-dependent enzymes such as thymidylate synthase
(TYMS) and 5-aminoimidazole-4-carboxyamide ribonu-
cleotide formyltransferase, ultimately blocking both thy-
midylate and purine syntheses [38, 40–42]. MTX
polyglutamates with chains longer than 3 glutamate residues
cannot be exported out of the cell, therefore, they get
deglutamated by the lysosomal γ-glutamyl hydrolase. The
balance between polyglutamation and deglutamation gen-
erates a steady state level of intracellular MTX. Lastly,
MTX gets exported from the cell by the ATP-binding cas-
sette proteins (ABCC1-4 and ABCG2). ATP-binding cas-
sette proteins play a unique role as they form a defence
network against a number of chemotherapy agents and
cellular toxins [43]. Furthermore, overexpression of these
efflux transporters has been associated with antifolate
resistance [44].
Cellular effect of MTX treatment
A number of studies have aimed to further describe the
mechanism of action of MTX. MTX treatment causes
accumulation of AICAR leading to activation of AMPK in
breast and prostate cancer cell lines [45]. Induction of
AMPK through MTX was found to promote glucose uptake
and lipid oxidation, as well as inhibiting protein synthesis,
linking the anti-proliferative effects of MTX to AMPK
activation [45–47] (Fig. 4). Interestingly, Savino et al. [48]
demonstrated that leukaemic cells that migrate to CNS
upregulate fatty acid synthetic pathways. It could be
hypothesised that MTX-induced fatty acid oxidation can
have an antiproliferative effect in these cells that are
depending on fatty acids.
Sengupta et al. [49], while investigating the effect of
AICAR in ALL cell lines, found that AICAR-mediated
AMPK activation inhibited cell proliferation, induced cell
cycle arrest and apoptosis. In addition, cells treated with
AICAR exhibited activation of the phosphatidylinositol 3-
kinase/protein kinase B (PI3K/Akt) signalling pathway and
inhibition of mTOR. Beckers et al. [50] suggested that MTX
enhances the antianabolic and antiproliferative effects of cell
permeable AICAR treatment, where MTX and AICAR
treatment were found to have a synergistic effect. Similarly,
Kuznetsov et al. [51] demonstrated that AICAR potentiates
MTX-induced ROS accumulation and consequently ER
stress. They hypothesise that AICAR in combination with
MTX treatment, and in conjugation with the upregulation of
PI3K/Akt pathway that inhibits AMPK, leads to prolonged
cellular ER stress that ultimately results in cell death. While
PI3K/Akt pathway normally exhibits a pro-oncogenic role, in
this model it seems to play a pro-apoptotic role. Furthermore,
mTOR inhibitors have been found to downregulate DHFR
expression and increase sensitivity to MTX both in vitro and
in vivo. These findings also led to a pilot clinical trial that
aimed to investigate such combination treatment in adults
with relapsed ALL [52]. As one of the main mechanisms of
MTX resistance is upregulation of DHFR expression, the fact
that mTOR inhibitors might have an effect on this enzyme is
something that needs to be further investigated.
Papadopoli et al. [53] demonstrated a similar effect when
MTX was combined with biguanides (metformin, phenfor-
min; display AMPK-dependent anti-tumorigenic effects),
stimulating discussion on how biguanides can be used to
improve chemotherapeutic response to antifolates. Indeed,
there has been increasing interest in repurposing biguanides
for cancer treatment. Interestingly, at clinically relevant
concentrations, metformin was found to induce folate
cofactors to become trapped as 5-formimino-THF, a cofactor
that cells seem to be unable to use for 1C units, ultimately
blocking DNA and RNA synthesis. This antifolate
behaviour of metformin can potentially present a major
Fig. 3 Mechanism of action of methotrexate. Methotrexate (MTX)
enters the cell mainly through the reduced folate carrier (RFC1) and to
a lesser extend through receptor-mediated endocytosis via a folate
receptor (FR). Upon entry, MTX gets polyglutamated (MTX(Glu)n) by
folylpolyglutamate synthase (FPGS). Polyglutamates of MTX are a
superior antifolate agent compared to MTX, capable of highly potent
irreversible inhibition of DHFR. Furthermore, MTX induces inhibition
of other enzymes like TYMS and GART/ATIC, ultimately blocking de
novo thymidylate and purine syntheses. γ-glutamyl hydrolase (γ-GH)
(compartmentalised in lysosomes) removes glutamate residues from
MTX, while ATP-binding cassette (ABC) transporters assist in the
excretion of MTX from the cell.
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mechanism of its anticancer effect, linked to an AMPK-
dependent anti-neoplastic response [54]. The fact that met-
formin behaves as an antifolate and activates AMPK might
explain why it synergises with MTX. In addition to its
antitumour activity, metformin was found to ameliorate
MTX-induced hepatorenal toxicity in an in vivo model.
Kanarek et al. [55] suggested that the histidine degradation
pathway also influences the sensitivity to MTX in leukaemia
xenografts, suggesting that histidine dietary intervention
could potentially be exploited to improve efficacy.
Clinical application of MTX
It is worth mentioning that usually patients with ALL and
lymphoma receive intravenously delivered MTX doses of
500 mg/m2 or higher, known as high-dose MTX. Such
dosages are routinely used to treat CNS ALL, where con-
ventional doses of MTX fail to protect against CNS relapse.
Doses of up to 33.6 g are being utilised to provide sig-
nificant MTX exposure in sites like CNS [56–59]. High-
dose MTX treatment can have adverse effects in patients,
leading to significant morbidity and even mortality [60].
Toxicity is primarily caused by delayed MTX excretion and
persistent high plasma MTX levels as a result of MTX-
induced renal dysfunction [61]. Gastrointestinal mucosal
injury, bone marrow suppression, renal or liver impairment
are some of the adverse effects caused by high-dose MTX
[11, 12]. Nilsson et al. [62] showed that DHFR and TYMS
are expressed in many proliferating tissues, in which the
adverse effects of MTX are observed. In agreement with the
DHFR and TYMS expression pattern, MTX has been
shown to accumulate in bone marrow cells and intestinal
mucosa both in vitro and in vivo. Even though malignant
cell lines have shown a markedly greater capacity to convert
MTX to polyglutamates, emergence of MTX poly-
glutamates is dose and time dependent, thus making highly
replicating cells, with high demands of purine and thymi-
dylate synthesis, susceptible to MTX-induced toxicity [63–
66]. Furthermore, Barredo and Moran [67] described that
FPGS activity is linked to proliferation rate and differ-
entiation stage. In other words, highly proliferating tissues
and immature cells exhibit an increased activity of FPGS.
These findings can give some clues about the susceptibility
of these tissues to antifolates; however, it would be inter-
esting to further assess differences of FPGS, FPGH activity,
expression of MTX influx and efflux transporters between
malignant cells and other highly proliferating cells.
Approaches to minimise MTX toxicity
Combination treatments of MTX with leucovorin (folinic
acid), or lower doses of MTX, are strategies that have been
developed to minimise adverse effects. Nevertheless, low-
dose MTX has been reported to cause pneumonitis and
Fig. 4 Metabolic changes
caused by MTX treatment.
MTX by inhibiting de novo
purine synthesis causes
significant accumulation of
AICAR. AICAR is an activator
of 5’ AMP-activated protein




such as glycolysis, autophagy,
lipid oxidation and oxidative
phosphorylation etc. to augment
cellular bioenergetic capacity.
Concurrently, AMPK inhibits
anabolic processes such as
protein and lipid synthesis and
ultimately restrains cellular
proliferation.
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leukoencephalopathy in patients with rheumatoid arthritis,
where MTX is a standardised treatment [12, 68]. Leucov-
orin is a structural analogue of MTX, thus it can compete
for membrane transport, polyglutamation and binding to
DHFR. However, as it does not require reduction by DHFR,
it can restore reduced folate pool even in the presence of
MTX [69, 70]. MTX polyglutamates have the tendency to
persist in malignant and normal cells even after the removal
of extracellular MTX, making the addition of leucovorin
essential for the rescue of normal tissues [71]. Nonetheless,
in vitro and in vivo studies have demonstrated that high
doses of leucovorin associate to higher risk of relapse
possibly by rescuing malignant cells from the effect of high-
dose MTX [70, 72, 73]. Skärby et al. [58] using the Nordic
Society of Paediatric Haematology and Oncology database
showed that high doses of leucovorin during a high-dose
MTX regime correlated with an increased risk of relapse in
ALL patients. Surprisingly, these patients demonstrated
high plasma MTX levels and longer elimination time, which
normally correlate with a better prognosis.
Administration of glucarpidase followed by leucovorin
treatment is another strategy that has been exploited in
patients who do not demonstrate the expected MTX clear-
ance. Glucarpidase cleaves MTX into two nontoxic meta-
bolites, 2,4-diamino-N-10-methylpteroic acid and
glutamate, providing a method to rapidly remove MTX in
patients with renal dysfunction. It rapidly decreases plasma
MTX, but it does not have any effect in intracellular MTX
concentration, thus patients still need to receive leucovorin.
Vigorous hydration and urinary alkalinization prior to MTX
infusions are additional care measures that are routinely
used to minimise toxicity [60]. Furthermore, a concomitant
treatment regime of MTX with asparaginase has been
developed to treat patients with relapsed and refractory
ALL. In addition, Buaboonnam et al. [74] demonstrated that
the combination of the two agents had efficacy in 6 out of
15 children with refractory or relapsed AML after salvage
chemotherapy. Asparaginase is thought to act as a ‘rescue’
agent and permit administration of normally toxic doses of
MTX [75, 76]. Early in vitro studies stressed out the
importance of the sequence of the administration of the two
agents, as asparaginase was shown to have antagonistic
effect to MTX when it is administrated prior to the anti-
folate [75, 77, 78]. However, recent studies have suggested
that schedule-related antagonism might not be as important
in vivo [79, 80]. Asparaginase does not seem to contribute
to additional MTX toxicity, but it also does not ameliorate
any of the adverse effects of high-dose MTX [80].
Antifolate resistance
Another issue that arises with MTX treatment is drug
resistance. Mutations in SLC19A1, amplification or
mutation of DHFR, and loss of polyglutamation have been
shown to contribute to the loss of efficacy [8, 9, 42]. Apart
from acquired resistance to MTX, an interesting aspect is
the intrinsic resistance. Even though AML cell lines show
high sensitivity to MTX (Fig. 1) blast cells from AML
patients appear to have a reduced ability to form long-chain
polyglutamates compared to cells from ALL patients,
making them unable to retain substantial amounts of MTX
[10]. This inability to form long-chain polyglutamates has
been linked to increased expression of ABC efflux trans-
porters, low activity of FPGS and high activity of γ-GH,
responsible for the degradation of the glutamate side chain
[81–83] (Fig. 3). Interestingly, a number of studies have
described that MTX polyglutamation in samples from acute
monocytic leukaemia patients (AML-M5) and acute
megakaryocytic leukaemia (AML-M7) patients is compar-
able to paediatric B-ALL patient samples [84, 85]. Rots
et al. [86] observed poor MTX polyglutamation in AML-
M5 samples, but an increases sensitivity to MTX compared
to AML-nonM5. In support to this, a closer look to the
AML cell lines in the Genomics of Drug Sensitivity in
Cancer database (https://www.cancerrxgene.org/) (Fig. 1)
demonstrates that AML-M5 cell lines (e.g. THP1,
MOLM13, MONO-Mac-6) show pronounced sensitivity to
MTX, contributing directly to the overall high sensitivity of
AML cell lines to MTX. Further investigation with regards
to MTX polyglutamation in AML-M5 is required to eval-
uate the possible use of MTX as a treatment. However,
intrinsic resistance is a noteworthy issue, as it points to the
critical need of new ways to target 1C metabolism that
could potentially overcome the need for intracellular
polyglutamation.
Pralatrexate (PDX), a MTX analogue, was designed to
have improved cellular transport via RFC-1 and enhanced
formation of polyglutamates, resulting in greater intracel-
lular retention [87]. In 2009, PDX was approved for the
treatment of relapsed or refractory T-cell lymphoma and in
a recent study it was shown to have anti-tumour activity in
preclinical models of multiple myeloma (MM) [88]. In
addition, pemetrexed, another anti-folate that shows high
affinity for both DHFR and TYMS, was described to cause
cell cycle blockage and consequently apoptosis in MM cells
in vitro and also in animal models in vivo [89]. However,
pemetrexed and pralatrexate target predominantly DHFR
implying that they can have similar limitations regarding
toxicity in normal tissues and drug resistance as MTX.
Additional purine and pyrimidine synthesis
inhibitors
Inhibitors that directly target purine or pyrimidine synthesis
has also been applied in haematological malignancies.
6-mercaptopurine (6-MP), is a thio-substituted purine
M. M. Zarou et al.
analogue that inhibits de novo purine synthesis. Burchenal
et al. [90] demonstrated that 6-MP induced temporary
remission in childhood leukaemia. Together with MTX, 6-
MP is universally used as maintenance therapy in childhood
ALL [91]. This purine analogue is converted into 6-
thioguanine nucleotide and 6-methylmercaptopurine (6-
MMPN), whose concentration impacts drug response and
toxicity. However, during 6-MP/MTX maintenance ther-
apy, increased levels of 6-MMPN correlate with hepato-
toxicity, a frequent side effect of the therapy [92]. In
addition, inhibitors of de novo pyrimidine synthesis have
shown promising results in blood cancers. More specifi-
cally, inhibitors of dihydrooratate dehydrogenase
(DHODH), an enzyme located in the inner membrane of the
mitochondria that catalyses the fourth step of de novo
pyrimidine synthesis, have emerged as therapeutic targets in
AML and MM. Leflunomide, one of the DHODH inhibitors
developed, was found to induce cell cycle arrest and
apoptosis through inhibition of c-Myc [93, 94]. Recently, a
novel DHODH inhibitor was shown to induce differentia-
tion in different models of AML in vitro and to prolong
survival in AML animal models [95].
Emerging strategies to target 1C metabolism in
blood cancers
A number of recent studies have tried to reveal novel
strategies to target 1C metabolism. Nilsson et al. [62]
demonstrated that among 1454 metabolic enzymes exam-
ined, MTHFD2 is the most consistently overexpressed in
tumours, while SHMT2 is the fifth. Vazquez et al. [96]
proposed that expression of mitochondrial 1C metabolism
enzymes determine the response to MTX. On that note,
García-Cañaveras et al. [97] showed that a dual inhibitor of
SHMT1/2, SHIN2, synergises with MTX both in vitro and
in vivo. More specifically, as a single agent SHIN2 inhib-
ited the proliferation of T-ALL cell lines and increased
survival in NOTCH1-driven mouse T-ALL models. Fur-
thermore, it sensitised MTX-resistant human T-ALL cells.
In support of this study, Pikman et al. [98] showed that T-
ALL cell lines that had developed resistance to MTX,
remained sensitive to dual inhibition of SHMT1/2. The
authors also demonstrated that loss of both SHMT1 and
SHMT2 activity was required for the anti-proliferative
effect that was observed, whereas repression of each
enzyme alone was not enough to elicit such an effect. The
findings reported reinforce the idea that there is a redun-
dancy between SHMT1 and SHMT2 and one can com-
pensate for the loss of the other. Thus, to block production
of 1C units from serine, simultaneous inhibition of both
enzymes is necessary. It can be hypothesised that the
synergistic effect of MTX with SHMT inhibitors might be a
result of the depletion of THF (SHMT substrate) by MTX,
therefore sensitising cells to SHMT inhibition (Fig. 5a). In
MTX resistant cells, decrease of MTX polyglutamates due
to decreased RFC1 or FPGS activity or increased γ-GH
Fig. 5 Hypothesised mechanisms of action of SHMT inhibitors. a
Proposed mechanism of synergy of MTX with SHMT inhibitors.
Inhibition of DHFR by MTX decreases intracellular THF, thus, it
sensitises cells to SHMT inhibitors. b Proposed mechanism of
increased sensitivity to SHMT inhibitors due to MTX resistance.
Decreases transport mediated by RFC1, decreased polyglutamation
due to decreased activity of FPGS or increased activity of γ-GH are
mechanisms that contribute to MTX resistance. Decreased MTX(Glu)n
correlates with decreased THF(Glu)n as folate has a similar influx
mechanism and polyglutamation pattern. As THF is a substrate for the
SHMT reaction, depletion of this substrate leads to increased sensi-
tivity of the cells to the SHMT inhibitors.
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would result in decrease of THF-polyglutamates, as folate
has a similar influx mechanism and polyglutamation pat-
tern. Therefore, a decrease in THF-polyglutamates due to
the MTX resistance would deplete the substrate of the
SHMT reaction and make cells sensitive to SHMT inhibi-
tors (Fig. 5b).
In the context of lymphoma, diffuse large B-cell lym-
phoma was shown to have a defective glycine import,
making it sensitive to pharmacological SHMT inhibition
[99]. This effect is explained by the fact that inhibition of
mitochondrial metabolism makes cells glycine auxotrophs,
depending on extracellular glycine uptake. In such circum-
stances, inhibition of the mitochondrial compartment would
be enough to sensitise cells, as the cytosolic compartment
cannot compensate for the lack of mitochondrial glycine
production, as we previously mentioned. Lometrexol, an
antifolate that targets GART, was found to have high affinity
for SHMT2 [100]. Selective SHMT2 inhibitors could be
useful for the treatment of malignancies like diffuse large B-
cell lymphoma where glycine uptake is impaired and cancer
cells are solemnly depending on mitochondrial 1C metabo-
lism for glycine production. Lastly, it was reported that loss
of MTHFD2 impaired growth and induced differentiation in
AML cell lines and primary AML blasts, while it decreased
leukaemia burden in human xenograft and MLL-AF9 mouse
leukaemia models. In the same study authors described that
AML cell lines characterised by a FMS-like tyrosine kinase
3 internal tandem duplication (FLT3-ITD) mutation are more
sensitive to loss of MTHFD2 [101]. In an attempt to further
characterise the metabolic changes in FLT3-ITD driven
AML, Bjelosevic et al. [102] demonstrated that FLT3-ITD
modulates serine synthesis and uptake as well as enzymes
involved in 1 C metabolism.
The cancer cells response to SHMT1/2 inhibitors exhi-
bits a metabolic pattern with many similarities to what
observed for MTX. By depriving cells from 1C units and
glycine, SHMT inhibitors block purine and thymidylate
synthesis. SHMT inhibitors also promote an increase in
AICAR levels and activation of AMPK [28], as observed
for MTX. This evidence suggests that SHMT inhibitors
have a mechanism of action similar to antifolates. Yet, by
acting on a different enzyme and being independent of
folate transporters, SHMT inhibitors may help to overcome
resistance to MTX.
Conclusion
Folate-mediated 1C metabolism comprises of a series of
metabolic reaction that contribute to biosynthetic processes.
As highly proliferating cells, including malignant cells, show
dependence on folate metabolism to fulfil their biosynthetic
needs, folate metabolism is increasingly gaining interest in
the research community. Studies of the recent years have
tried to shed light on the biological importance of the
compartmentalisation of the pathway, formate overflow, as
well as NADH and NADPH by-products. Its implications in
cancer have given rise to modern cancer therapy. Anti-
folates, especially MTX, are being routinely used to treat
various neoplastic diseases and they have found a significant
application in many haematological malignancies. However,
as we described above, side effects and resistance to anti-
folates are problems that are yet to be resolved, highlighting
the need of new approaches to target this pathway.
Targeting enzymes associated with serine 1C metabolism
might overcome the drug resistance that has been described
for traditional antifolates. What makes them attractive is
that they do not require any folate transporters or intracel-
lular polyglutamation. Since 2017, when Ducker et al. [99]
described the first pharmacological inhibitor of SHMT2/1,
these inhibitors have shown promising results, especially in
T-ALL leukaemia, as single agents but also in combination
with MTX [97, 98]. These encouraging results could have
implications in other blood cancers like AML and MM
where effective treatment options are limited; however, this
still requires further investigation. In addition, Oizel et al.
[28] suggested that inhibition of SHMT2/1 causes accu-
mulation of AICAR and activation of AMPK, as seen with
MTX. Therefore, further understanding of the mechanism
of action of these inhibitors would potentially help to
explore new therapeutic approaches.
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